- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | Jul 29, 2023
Discovery & Translation
Turning cancer drivers into cell death drivers; plus LNPs to edit stem cells and more
BioCentury’s roundup of translational innovations
BioCentury | Jun 3, 2022
Deals
With standard-of-care aim for precision therapy, BMS pays high premium for Turning Point
In $4.1B deal, pharma pays more than double the biotech’s market valuation to gain targeted lung cancer therapy repotrectinib
BioCentury | Dec 22, 2021
Management Tracks
Nobel winning chemist Grubbs passes
Longtime Caltech professor served on Aileron’s SAB
BioCentury | Apr 2, 2020
Distillery Therapeutics
CDC42BPA inhibition for high-grade serous ovarian carcinoma
BioCentury | Nov 17, 2018
Preclinical News
Spotlight co-founder uses CRISPR screen to ID T cell regulator genes for cancer
Items per page:
1 - 10 of 75